title: Efficacy and safety of basiliximab in kidney transplantation.
abstract: The efficacy and safety of basiliximab, in combination with different maintenance regimens, are extensively addressed in the available literature. Basiliximab reduces the incidence of acute rejection, allows a safe reduction of steroid dosage, and is associated with economic savings, although there is substantially no proof that basiliximab prolongs either patient or graft survival. Initial basiliximab administration entails a low-risk and is associated with fewer adverse events than T cell depleting agents. However, life-threatening reactions were reported following re-exposure to basiliximab in recipients who lost graft function early after transplantation and, therefore, discontinued all immunosuppressive agents.
authors.affiliation: Division of Surgery in Uremic and Diabetic Patients (General and Transplant Surgery), Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy. uboggi@med.unipi.it
authors.forename: Ugo
authors.initials: U
authors.lastname: Boggi
authors.forename: Fabio
authors.initials: F
authors.lastname: Vistoli
authors.forename: Stefano
authors.initials: S
authors.lastname: Signori
authors.forename: Marco
authors.initials: M
authors.lastname: Del Chiaro
authors.forename: Gabriella
authors.initials: G
authors.lastname: Amorese
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Barsotti
authors.forename: Gaetano
authors.initials: G
authors.lastname: Rizzo
authors.forename: Piero
authors.initials: P
authors.lastname: Marchetti
authors.forename: Romano
authors.initials: R
authors.lastname: Danesi
authors.forename: Mario
authors.initials: M
authors.lastname: Del Tacca
authors.forename: Franco
authors.initials: F
authors.lastname: Mosca
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000077552:Basiliximab; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D017850:Economics, Pharmaceutical; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation; D011993:Recombinant Fusion Proteins / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012307:Risk Factors; D013601:T-Lymphocytes
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab